Krystal Biotech (NASDAQ:KRYS) Receives “Overweight” Rating from Cantor Fitzgerald

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a report issued on Thursday,Benzinga reports. They presently have a $215.00 price objective on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 14.36% from the stock’s current price.

A number of other brokerages have also recently issued reports on KRYS. Chardan Capital upped their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday. HC Wainwright restated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Wednesday. Finally, Citigroup upped their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and an average target price of $208.71.

Krystal Biotech Price Performance

NASDAQ:KRYS traded up $11.84 during trading hours on Thursday, reaching $188.01. The company’s stock had a trading volume of 150,103 shares, compared to its average volume of 245,822. The company has a market cap of $5.41 billion, a price-to-earnings ratio of 105.99 and a beta of 0.84. Krystal Biotech has a one year low of $107.50 and a one year high of $219.34. The business’s 50-day moving average is $157.40 and its 200-day moving average is $175.17.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.30 earnings per share. On average, sell-side analysts predict that Krystal Biotech will post 3.22 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Krystal Biotech in the third quarter valued at about $40,000. Values First Advisors Inc. bought a new stake in shares of Krystal Biotech in the third quarter valued at about $53,000. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech in the fourth quarter valued at about $95,000. Huntington National Bank raised its position in Krystal Biotech by 97.6% in the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after purchasing an additional 283 shares in the last quarter. Finally, Blue Trust Inc. raised its position in Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after purchasing an additional 412 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).